Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mitiglinide calcium hydrate (S-21403 calcium hydrate) is a drug for the treatment of type 2 diabetes. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells. Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | In stock | $ 41.00 | |
500 mg | In stock | $ 121.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 45.00 |
Description | Mitiglinide calcium hydrate (S-21403 calcium hydrate) is a drug for the treatment of type 2 diabetes. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells. Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. |
Synonyms | KAD-1229 calcium hydrate, Mitiglinide calcium, S-21403 calcium hydrate |
Molecular Weight | 704.91 |
Formula | C38H52CaN2O8 |
CAS No. | 207844-01-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (35.47 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mitiglinide calcium hydrate 207844-01-7 Membrane transporter/Ion channel Potassium Channel KAD-1229 calcium hydrate insulinotropic hypoglycaemic S-21403 KAD1229 Inhibitor S-21403 calcium Hydrate Mitiglinide calcium KcsA diabetes inhibit KAD 1229 anti-diabetic KAD-1229 calcium Hydrate S-21403 calcium hydrate S21403 KAD-1229 type Mitiglinide calcium Hydrate S 21403 inhibitor